Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin

William M. Miller, Clinton A. Medbery, Daniel L. Clarke-Pearson, Alan Barker, Russell Hull, Terry Delmore, Edward Genton, Jack Hirsh, Michael Gent, David Sackett, Dermot Mcloughlin, Peter Armstrong

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

Original languageEnglish (US)
Pages (from-to)752-753
Number of pages2
JournalNew England Journal of Medicine
Volume302
Issue number13
DOIs
StatePublished - Mar 27 1980

Fingerprint

Warfarin
Venous Thrombosis
Heparin
Antithrombins
Antithrombin III
Intravenous Infusions
Thrombin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Miller, W. M., Medbery, C. A., Clarke-Pearson, D. L., Barker, A., Hull, R., Delmore, T., ... Armstrong, P. (1980). Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin. New England Journal of Medicine, 302(13), 752-753. https://doi.org/10.1056/NEJM198003273021316

Prevention of Recurrent Venous Thrombosis : Warfarin versus Heparin. / Miller, William M.; Medbery, Clinton A.; Clarke-Pearson, Daniel L.; Barker, Alan; Hull, Russell; Delmore, Terry; Genton, Edward; Hirsh, Jack; Gent, Michael; Sackett, David; Mcloughlin, Dermot; Armstrong, Peter.

In: New England Journal of Medicine, Vol. 302, No. 13, 27.03.1980, p. 752-753.

Research output: Contribution to journalLetter

Miller, WM, Medbery, CA, Clarke-Pearson, DL, Barker, A, Hull, R, Delmore, T, Genton, E, Hirsh, J, Gent, M, Sackett, D, Mcloughlin, D & Armstrong, P 1980, 'Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin', New England Journal of Medicine, vol. 302, no. 13, pp. 752-753. https://doi.org/10.1056/NEJM198003273021316
Miller WM, Medbery CA, Clarke-Pearson DL, Barker A, Hull R, Delmore T et al. Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin. New England Journal of Medicine. 1980 Mar 27;302(13):752-753. https://doi.org/10.1056/NEJM198003273021316
Miller, William M. ; Medbery, Clinton A. ; Clarke-Pearson, Daniel L. ; Barker, Alan ; Hull, Russell ; Delmore, Terry ; Genton, Edward ; Hirsh, Jack ; Gent, Michael ; Sackett, David ; Mcloughlin, Dermot ; Armstrong, Peter. / Prevention of Recurrent Venous Thrombosis : Warfarin versus Heparin. In: New England Journal of Medicine. 1980 ; Vol. 302, No. 13. pp. 752-753.
@article{c328692163c148f9b3fce4ceac64c565,
title = "Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin",
abstract = "To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.",
author = "Miller, {William M.} and Medbery, {Clinton A.} and Clarke-Pearson, {Daniel L.} and Alan Barker and Russell Hull and Terry Delmore and Edward Genton and Jack Hirsh and Michael Gent and David Sackett and Dermot Mcloughlin and Peter Armstrong",
year = "1980",
month = "3",
day = "27",
doi = "10.1056/NEJM198003273021316",
language = "English (US)",
volume = "302",
pages = "752--753",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - Prevention of Recurrent Venous Thrombosis

T2 - Warfarin versus Heparin

AU - Miller, William M.

AU - Medbery, Clinton A.

AU - Clarke-Pearson, Daniel L.

AU - Barker, Alan

AU - Hull, Russell

AU - Delmore, Terry

AU - Genton, Edward

AU - Hirsh, Jack

AU - Gent, Michael

AU - Sackett, David

AU - Mcloughlin, Dermot

AU - Armstrong, Peter

PY - 1980/3/27

Y1 - 1980/3/27

N2 - To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

AB - To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

UR - http://www.scopus.com/inward/record.url?scp=1642527277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642527277&partnerID=8YFLogxK

U2 - 10.1056/NEJM198003273021316

DO - 10.1056/NEJM198003273021316

M3 - Letter

C2 - 7354791

AN - SCOPUS:1642527277

VL - 302

SP - 752

EP - 753

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -